Table 2. Clinical validation of MRD... | American Society of Hematology

Table 2.

Clinical validation of MRD before and after transplant

Study	Patients (N)	Patient group	MRD method	Time point	Threshold	Outcome	References
Meta-analysis	1431	Adult non-APL	MFC and molecular	Pretransplant	0.1% for FCM	Prognostic for relapse and survival	45
EORTC/GIMEMA	81	MRD+ eligible for SCT	MFC	After consolidation	0.035%	No contraindication for allo-SCT in MRD+ patients	75
IRCCS Genoa	224	Transplanted in CR1/CR2	MFC and WT1	Pretransplant	2.5 × 10⁻⁴ 250 copies/Abl × 10⁴	Prognostic value of MRD for pre- and posttransplant interventions	69
Toronto/Korea	104	Adult AML eligible for transplant	NGS	Diagnosis and pre- and posttransplant (day 21)	VAF^0.2%-post-HCT^D21	Good prediction of relapse	76
Seattle	279	Adult	MFC	Pre- and posttransplant	0.1%	MRD+ poor prognosis irrespective of myeloablative conditioning	77
Hannover	116	>18 y	NGS	In CR before transplant	Error corrected	Predictive for relapse and survival Refine SCT	21
RELAZA2	60	MRD+ >18 y	NPM1 fusion gene, CD34 Chimerism MFC	After induction/consolidation Preemptive	Depending on test used	Predictive for relapse	50

Study	Patients (N)	Patient group	MRD method	Time point	Threshold	Outcome	References
Meta-analysis	1431	Adult non-APL	MFC and molecular	Pretransplant	0.1% for FCM	Prognostic for relapse and survival	45
EORTC/GIMEMA	81	MRD+ eligible for SCT	MFC	After consolidation	0.035%	No contraindication for allo-SCT in MRD+ patients	75
IRCCS Genoa	224	Transplanted in CR1/CR2	MFC and WT1	Pretransplant	2.5 × 10⁻⁴ 250 copies/Abl × 10⁴	Prognostic value of MRD for pre- and posttransplant interventions	69
Toronto/Korea	104	Adult AML eligible for transplant	NGS	Diagnosis and pre- and posttransplant (day 21)	VAF^0.2%-post-HCT^D21	Good prediction of relapse	76
Seattle	279	Adult	MFC	Pre- and posttransplant	0.1%	MRD+ poor prognosis irrespective of myeloablative conditioning	77
Hannover	116	>18 y	NGS	In CR before transplant	Error corrected	Predictive for relapse and survival Refine SCT	21
RELAZA2	60	MRD+ >18 y	NPM1 fusion gene, CD34 Chimerism MFC	After induction/consolidation Preemptive	Depending on test used	Predictive for relapse	50

ABL, Abelson gene; allo-SCT, allogeneic SCT; CR, complete remission; FCM, flow cytometry post-HCTD21, day 21 after hematopietic cell transplantation; VAF, variant allele frequency.